PATIENT ALERT: If you have tested positive for COVID in the last 14 days, please notify us and reschedule your appointment. Online COVID pre-screening is REQUIRED 72 hours prior to your appointment. Please CLICK HERE to complete the questionnaire.  Masks are still required in all offices.   Information regarding COVID-19.  

Clinical Research & Trials

USO 20396

Available Locations Critical Document Checklist SAE List my Site 20396 Patients Training Log Generate Document(Florence) my Site 20396 Training Monitoring Calendar CRF Summary A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) (D967UC00001)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

-Advanced or metastatic HER 2+ breast cancer with measurable disease and no prior chemotherapy or HER 2+ targeted therapy in the advanced or metastatic setting.
-No: HIV, active Hepatitis B or Hepatitis C; myocardial infarction within past 6 months, symptomatic congestive heart failure (NYHA Class II – IV); clinically significant pulmnary disorder such as severe asthma or chronic obstructive pulmonary disorder (COPD), prior pneumonectomy; history of arrhythmia which is symptomatic and requires treatment such as uncontrolled atrial fibrillation,asymptomatic, sustained ventricular tachycardia (if controlled by medications or pacemaker allowed); history of interstitial lung disease (ILD)/pneumonits that required steriods or current or suspected ILD/pneumonitis.

Available at: